Bionomics Limited, (BNOX) News
Filter BNOX News Items
BNOX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BNOX News Highlights
- For BNOX, its 30 day story count is now at 2.
- Over the past 16 days, the trend for BNOX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- JAZZ, DEC and DRUG are the most mentioned tickers in articles about BNOX.
Latest BNOX News From Around the Web
Below are the latest news stories about BIONOMICS LIMITED that investors may wish to consider to help them evaluate BNOX as an investment opportunity.
Jazz Pharmaceuticals' (JAZZ) PTSD Drug Misses Study GoalsAfter a mid-stage study fails to show any improvement in its primary or secondary endpoints, Jazz (JAZZ) plans to scrap the development of its PTSD drug. |
Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual MeetingA psychometric analysis concluded that Subjective Units of Distress Scale (SUDS) is a psychometrically valid, sensitive, and reliable tool for evaluation of social anxiety.SUDS will be used as the primary outcome in future Phase 3 social anxiety disorder (SAD) clinical trials. ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion c |
12 Best Stocks For Day TradingIn this piece, we will take a look at the 12 Best Stocks For Day Trading. If you want to skip our introduction to trading indicators and the economic climate, then check out 5 Best Stocks For Day Trading. The modern day stock market is significantly different from the one of the early 1900s. These […] |
Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety DisorderPositive outcome of End-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA) in September 2023 enables advancement of BNC210 into Phase 3 studies in Social Anxiety DisorderCompany confirms agreement with the FDA on Phase 3 clinical program and alignment on nonclinical toxicology studies required for registrationCompany is on track for first patient dosed in the Phase 3 program planed for Q1’24 ADELAIDE, Australia, and CAMBRIDGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Bionomics Limit |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayPre-market stock movers are worth checking out on Monday as we start off the week with all the latest news this morning! |
Bionomics Full Year 2023 Earnings: AU$3.60 loss per share (vs AU$0.016 loss in FY 2022)Bionomics ( NASDAQ:BNOX ) Full Year 2023 Results Key Financial Results Net loss: AU$31.8m (loss widened by 46% from FY... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's time for a dive into the biggest pre-market stock movers as we check out all of the latest news traders need to know about on Friday! |
Bionomics (BNOX) Meets Goals in PTSD Study, Stock Rallies 244%Bionomics (BNOX) announces positive top-line results from its mid-stage study of BNC210 for the treatment of Post-Traumatic Stress Disorder. The stock of the company rallies 244%. |
Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced positive topline results from its Phase 2b ATTUNE trial of BNC210 for the treatment of PTSD, as described more fully below. |
Why Is Ascent Solar Technologies (ASTI) Stock Down 58% Today?Ascent Solar Technologies stock is taking a beating on Thursday following the launch of a $12.5 million share offering for ASTI. |